article thumbnail

The 3Rs Principles in Cosmetic and Self-care Industry: the Regulation that Prioritises Animal Welfare

biobide

With an increased focus on animal welfare , the beauty industry has undergone a shift towards the 3Rs Principle application and all surrounding regulations. In 2009 this ban was expanded to include a ban on the use of any ingredient tested on animals for cosmetic products.

article thumbnail

Tick Tock re Tik Tok and FDA’s OPDP

Eye on FDA

FDA’s OPDP began considering an approach to regulating social media long before Tik Tok came into being. Studying DTC on broadcast television isn’t going to get us there and an approach to regulating promotional speech in social media is increasingly not platform agnostic. In fact, the medium does matter.

FDA 89
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Moving Regulatory Landscape for Gene Therapy Trials in EU: Part 2

thought leadership

This EU portal is established as part of the new Clinical Trial Regulation No. In this respect, a clinical trial with a GMO must also comply with either the contained use Directive (2009/41/EC) or the deliberate release Directive (2001/18/EC).

Trials 52
article thumbnail

FDA Knows Its Own Strength—and It Includes Concentration

FDA Law Blog: Biosimilars

This of course, make sense—after decades of experience implementing the Hatch-Waxman, Congress and FDA had learned a few new tricks by 2009/2010. FDA replied that its definition of strength including concentration was clear even in 2009. FDA explained that its bioequivalence regulations at 21 C.F.R.

FDA 59
article thumbnail

Article Periodic Thank You What we expect EU regulators to do in December 2023

Agency IQ

What we expect EU regulators to do in December 2023 Welcome to AgencyIQ’s monthly roundup of EU chemical sector activities. Highlights of chemical regulatory activities Consultations open under the REACH and CLP regulations are coming to an end in December. Events happening next month include two ECHA meetings (i.e.,

article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law Blog: Biosimilars

Let’s just say, the smackdown—er, decision—eviscerates FDA’s approach to regulating flavored e-cigarettes. This story goes back to the 2009 Family Smoking Prevention and Tobacco Control Act, which prohibits manufacturers from selling any “new tobacco product” without authorization from FDA. FDA failed on each count.

FDA 115
article thumbnail

FDA approves Novartis’ MS drug Kesimpta for treating relapsed forms of the disease

The Pharma Data

The US regulator originally approved the drug in 2009 for the treatment of chronic lymphocytic leukaemia as an intravenous infusion with a high dose that was administered by a healthcare provider. Kesimpta targets and delivers B-cell therapy and has shown to have superior efficacy and safety profile compared to similar treatments.